SG11202108274SA - Topical phosphoinositide 3-kinase inhibitors - Google Patents
Topical phosphoinositide 3-kinase inhibitorsInfo
- Publication number
- SG11202108274SA SG11202108274SA SG11202108274SA SG11202108274SA SG11202108274SA SG 11202108274S A SG11202108274S A SG 11202108274SA SG 11202108274S A SG11202108274S A SG 11202108274SA SG 11202108274S A SG11202108274S A SG 11202108274SA SG 11202108274S A SG11202108274S A SG 11202108274SA
- Authority
- SG
- Singapore
- Prior art keywords
- phosphoinositide
- topical
- kinase inhibitors
- kinase
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802093P | 2019-02-06 | 2019-02-06 | |
| US202062958049P | 2020-01-07 | 2020-01-07 | |
| PCT/US2020/016876 WO2020163525A1 (fr) | 2019-02-06 | 2020-02-05 | Inhibiteurs de phosphoinositide 3-kinase topiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108274SA true SG11202108274SA (en) | 2021-08-30 |
Family
ID=71835949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108274SA SG11202108274SA (en) | 2019-02-06 | 2020-02-05 | Topical phosphoinositide 3-kinase inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11661429B2 (fr) |
| EP (1) | EP3920911A4 (fr) |
| JP (1) | JP2022519317A (fr) |
| KR (1) | KR20210124310A (fr) |
| CN (1) | CN114072144A (fr) |
| AU (1) | AU2020219065A1 (fr) |
| BR (1) | BR112021015353A2 (fr) |
| CA (1) | CA3127686A1 (fr) |
| IL (1) | IL285020A (fr) |
| MA (1) | MA54907A (fr) |
| MX (1) | MX2021009142A (fr) |
| SG (1) | SG11202108274SA (fr) |
| TW (1) | TW202045513A (fr) |
| WO (1) | WO2020163525A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3127686A1 (fr) | 2019-02-06 | 2020-08-13 | Venthera, Inc. | Inhibiteurs de phosphoinositide 3-kinase topiques |
| CA3187759A1 (fr) * | 2020-08-04 | 2022-02-10 | Agis Kydonieus | Formulations d'inhibiteurs de phosphoinositide 3-kinase |
| IL311242A (en) * | 2021-09-15 | 2024-05-01 | Dermbiont Inc | Compositions and formulations for topical use of an AKT inhibitor for the prevention, treatment and improvement of skin diseases, conditions and disorders |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| JP3602519B2 (ja) | 2002-07-12 | 2004-12-15 | コナミ株式会社 | ビデオゲーム装置、画像処理方法及びプログラム |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| US20080199449A1 (en) | 2005-08-12 | 2008-08-21 | The General Hospital Corporation | Methods and Compositions for Use in Treating Vascular Diseases and Conditions |
| US8129371B2 (en) * | 2007-10-16 | 2012-03-06 | Wyeth Llc | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| MX2011007326A (es) * | 2009-01-08 | 2011-10-19 | Curis Inc | Inhibidores de fosfoinositida 3-quinasa con una porcion de enlace de cinc. |
| WO2011070499A1 (fr) | 2009-12-11 | 2011-06-16 | Wyeth Llc | Biomarqueurs de la voie de la phosphatidylinotisol-3-kinase |
| CN102268014B (zh) | 2010-06-03 | 2015-06-03 | 上海艾力斯医药科技有限公司 | 一类稠合杂芳基衍生物、制备方法及其应用 |
| GB201011771D0 (en) | 2010-07-13 | 2010-08-25 | Bioinvent Int Ab | Biological material and particular uses thereof |
| SI2627316T1 (sl) | 2010-10-13 | 2019-06-28 | Medivir Ab | Farmacevtska formulacija za zaviralce histonske deacetilaze |
| RU2014107713A (ru) | 2011-07-28 | 2015-09-10 | Дженентек, Инк | Модель рака молочной железы у животных, кроме человека, с активируемым pik3ca h1047r |
| US8871781B2 (en) | 2011-11-30 | 2014-10-28 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating a subject for a lymphatic malformation |
| KR101915942B1 (ko) | 2012-06-08 | 2018-11-06 | 에프. 호프만-라 로슈 아게 | 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물 |
| WO2014046617A1 (fr) | 2012-09-19 | 2014-03-27 | Agency For Science, Technology And Research | Compositions et méthodes de traitement du cancer |
| AU2016265844B2 (en) | 2015-05-15 | 2021-02-11 | Memorial Sloan-Kettering Cancer Center | Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations |
| JP7051693B2 (ja) | 2016-02-19 | 2022-04-11 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ） |
| US20170340649A1 (en) | 2016-05-30 | 2017-11-30 | Sun Pharmaceutical Industries Limited | Topical aqueous spray compositions of halobetasol |
| KR102358377B1 (ko) | 2016-12-28 | 2022-02-03 | 히사미쓰 세이야꾸 가부시키가이샤 | 첩부제 |
| CA3127686A1 (fr) | 2019-02-06 | 2020-08-13 | Venthera, Inc. | Inhibiteurs de phosphoinositide 3-kinase topiques |
-
2020
- 2020-02-05 CA CA3127686A patent/CA3127686A1/fr active Pending
- 2020-02-05 WO PCT/US2020/016876 patent/WO2020163525A1/fr active Application Filing
- 2020-02-05 MX MX2021009142A patent/MX2021009142A/es unknown
- 2020-02-05 MA MA054907A patent/MA54907A/fr unknown
- 2020-02-05 US US16/783,050 patent/US11661429B2/en active Active
- 2020-02-05 EP EP20752673.2A patent/EP3920911A4/fr active Pending
- 2020-02-05 KR KR1020217027706A patent/KR20210124310A/ko unknown
- 2020-02-05 AU AU2020219065A patent/AU2020219065A1/en active Pending
- 2020-02-05 JP JP2021545964A patent/JP2022519317A/ja active Pending
- 2020-02-05 SG SG11202108274SA patent/SG11202108274SA/en unknown
- 2020-02-05 BR BR112021015353-5A patent/BR112021015353A2/pt unknown
- 2020-02-05 CN CN202080027395.8A patent/CN114072144A/zh active Pending
- 2020-02-06 TW TW109103710A patent/TW202045513A/zh unknown
-
2021
- 2021-07-21 IL IL285020A patent/IL285020A/en unknown
-
2023
- 2023-04-10 US US18/297,698 patent/US20230416269A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230416269A1 (en) | 2023-12-28 |
| EP3920911A4 (fr) | 2023-03-08 |
| US20200247816A1 (en) | 2020-08-06 |
| CN114072144A (zh) | 2022-02-18 |
| BR112021015353A2 (pt) | 2021-10-05 |
| WO2020163525A1 (fr) | 2020-08-13 |
| MA54907A (fr) | 2022-05-11 |
| TW202045513A (zh) | 2020-12-16 |
| US11661429B2 (en) | 2023-05-30 |
| JP2022519317A (ja) | 2022-03-22 |
| IL285020A (en) | 2021-09-30 |
| KR20210124310A (ko) | 2021-10-14 |
| EP3920911A1 (fr) | 2021-12-15 |
| CA3127686A1 (fr) | 2020-08-13 |
| MX2021009142A (es) | 2021-10-13 |
| AU2020219065A1 (en) | 2021-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292642A (en) | ras inhibitors | |
| IL292643A (en) | ras inhibitors | |
| IL292644A (en) | ras inhibitors | |
| ZA202002770B (en) | Imidazo-pyridine compounds as pad inhibitors | |
| IL277006A (en) | CD73 inhibitors | |
| EP3843714A4 (fr) | Inhibiteurs de cd73 | |
| IL304348A (en) | cd73 inhibitors | |
| IL285020A (en) | Topical phosphoinositide 3-kinase inhibitors | |
| GB201705971D0 (en) | Inhibitor compounds | |
| HK1253279A1 (zh) | 磷酸肌醇-3-激酶抑制劑化合物和cdk4/6抑制劑化合物的用於治療癌症的組合 | |
| GB201819126D0 (en) | Inhibitor compounds | |
| IL290087A (en) | inhibitory substances | |
| SG11202110534QA (en) | Cd73 inhibitors | |
| SG11202005870RA (en) | Novel mtor inhibitor compounds | |
| GB201914860D0 (en) | Inhibitor compounds | |
| EP3814324A4 (fr) | Inhibiteurs de la cathepsine c | |
| EP3532044A4 (fr) | Compositions d'inhibiteur de hdac pour la réactivation du chromosome x | |
| GB201905328D0 (en) | Inhibitor compounds | |
| EP3865129A4 (fr) | Inhibiteur de l'activité de trpv4 | |
| EP3640250A4 (fr) | Composé utilisé en tant qu'inhibiteur de gls1 | |
| IL288323A (en) | Dopamine-b-hydroxylase inhibitors | |
| GB201905318D0 (en) | Inhibitor compounds | |
| GB201819136D0 (en) | Inhibitor compounds | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| GB201806130D0 (en) | Inhibitor compounds |